The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Items 501–600 of 710
Kuhn, E. P., Pirruccello, J. P., Boothe, J. T., Li, Z., Tosteson, T. D., Stahl, J. E., Schwartz, G. N., & Chamberlin, M. D. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06849-0 · Cited by 3
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools
Rassy, E., Benvenuti, C., Akla, S., Meglio, A. D., Martin, É., Havas, J., Rieutord, A., Combarel, D., Fasse, L., Scotté, F., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00655-1 · Cited by 3
Willis, K. D., Walsh, E. A., Dunderdale, L., Post, K. E., Horick, N., Antoni, M. H., Safren, S. A., Partridge, A. H., Peppercorn, J. M., Park, E. R., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00316 · Cited by 3
Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer
Cazzaniga, M. E., Huober, J., Tamma, A. V., Emde, A., Thoele, K., & O’Shaughnessy, J. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.12.011 · Cited by 4
Lau, C., LaBorde, K., Fatima, B., Alfartosy, S. S., Abughosh, S., Torre, R. M. D. L., Brown, E. N., & Trivedi, M. V. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07701-x · Cited by 3
Ebid, A. I. M., El-Shewy, R., Mostafa, M. I., Eid, R., Shash, E., & Mobarez, M. A. (2025) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2025.100682 · Cited by 3
Velarde, R. M., López, J. A. P., Venegas, J. M., & Álvarez, J. F. L. (2013) · Psicooncología · doi:10.5209/rev_psic.2013.v10.41953 · Cited by 3
Medication use in breast cancer survivors compared to midlife women
Otte, J. L., Skaar, T. C., Wu, J., Yu, M., Ryker, K., Burns, D. S., & Carpenter, J. S. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1727-5 · Cited by 3
COX2 induction: a mechanism of endocrine breast cancer resistance?
Clark, B. L., Murphy, M. A., & Kamdem, L. K. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4284-7 · Cited by 3
Sant, M., Meneghini, E., Bastos, J., Rossi, P. G., Guevara, M., Innos, K., Katalinic, A., Gil-Majuelo, L., Marcos‐Gragera, R., Molinié, F., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05761-9 · Cited by 4
Lemij, A. A., de Glas, N. A., Derks, M. G. M., Bastiaannet, E., Merkus, J. W. S., Lans, T. E., van der Pol, C. C., van Dalen, T., Vulink, A. J. E., van Gerven, L., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/s1879-4068(21)00420-3 · Cited by 3
Managing the Breast Cancer Survivor in Primary Care
Smania, M. A., Corey, B., & Schrader, K. E. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.11.007 · Cited by 3
Bright, E. E., Genung, S. R., Stanton, A. L., & Arch, J. J. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06705-1 · Cited by 3
Roche, N., Provost, J.-B. L., Borinelli-Franzoi, M. A., Boinon, D., Martin, É., Menvielle, G., Dumas, A., Rivera, S., Conversano, A., Matias, M., et al. (2022) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2022.102259 · Cited by 3
Thorén, L., Margolin, S., Eliasson, E., Bergh, J. C. S., & Lindh, J. D. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06887-2 · Cited by 3
Zeng, E., He, W., Sjölander, A., Bergqvist, J., Fang, F., & Czene, K. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae061 · Cited by 3
Assan, O. Q., Memoli, V., Guillaumie, L., Turcotte, V., Lemay, M., Dionne, A. R., Lemieux, J., Provencher, L., Gotay, C. C., de Bruin, M., et al. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01599-y · Cited by 3
Green, S. M. C., Rousseau, N. S., Hall, L., French, D., Graham, C. D., Lloyd, K. E., Collinson, M., Ow, P. L., Taylor, C., Howdon, D., et al. (2024) · Prevention Science · doi:10.1007/s11121-024-01711-9 · Cited by 3
Chen, Y., Lai, H.-W., Su, H., Loh, E.-W., Huang, T., & Tam, K. (2024) · Breast Cancer · doi:10.1007/s12282-024-01622-1 · Cited by 3
Immunologic Approaches to Breast Cancer Therapy
Stanton, S. E., Ramos, E., & Disis, M. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00071-4 · Cited by 4
Oral lesions and associated factors in breast cancer survivors
Jardim, L. C., Flores, P. T., Sensever, F. D. A., Araújo, M. D. C. D. S., de Moraes, C. M. B., Chiesa, J., & Antoniazzi, R. P. (2019) · Journal of Investigative and Clinical Dentistry · doi:10.1111/jicd.12447 · Cited by 3
Kamga, A. M., Martino, C. D., Anota, A., Paget‐Bailly, S., Coutant, C., Arveux, P., Desmoulins, I., & Dabakuyo‐Yonli, T. S. (2020) · Trials · doi:10.1186/s13063-020-04397-w · Cited by 3
Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study
Khobrani, A., Alatawi, Y. M., Bajnaid, E., Alemam, O., Osman, A., Attash, L. B., Jaffal, M., Al-Ghanmi, M. A., Alharbi, A. S., & Alnuhait, M. A. (2022) · Cureus · doi:10.7759/cureus.24780 · Cited by 3
Waaijer, M. E. C., Lemij, A. A., de Boer, A. Z., Bastiaannet, E., van den Bos, F., Derks, M. G. M., Kroep, J. R., Liefers, G., Portielje, J. E. A., & de Glas, N. A. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07029-4 · Cited by 3
Resistance to Resilience: Understanding Post-surgical Hormone Therapy in Breast Cancer Care
Kumar, T., Dutta, R. R., Thakre, S., Singh, A., Velagala, V. R., & Shinde, R. K. (2023) · Cureus · doi:10.7759/cureus.47869 · Cited by 3
Adjuvant hormonal therapy in young breast cancer patients
Lambertini, M., & Azim, H. A. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.67 · Cited by 3
Bedi, J. S., Mayo, R. M., Chen, L., Dickes, L., Sherrill, W. W., & Jones, K. O. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219835297 · Cited by 3
Ramin, C. A., Pfeiffer, R. M., Fan, S. X., Mullooly, M., Falk, R. T., Jones, K. M., Caporaso, N. E., Bey‐Knight, L., Sak, M. A., Simon, M. S., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00511-8 · Cited by 3
Moreau-Bachelard, C., Campion, L., Robert, M., Kerdraon, O., Renaudeau, C., Aumont, M., Classe, J., Campone, M., & Frenel, J. (2020) · Cancers · doi:10.3390/cancers12123725 · Cited by 3
Radiotherapy for elderly patients with low-risk breast cancer
Kaidar‐Person, O., Poortmans, P. M., Kuten, A., & Morgan, D. A. L. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70063-x · Cited by 3
Hubbard, T. J. E., Wright, G., Morgan, J. L., Martin, C., Walters, S. J., Cheung, K., Audisio, R. A., Reed, M., & Wyld, L. (2024) · The Breast · doi:10.1016/j.breast.2024.103768 · Cited by 2
Expanding Geographical Access to Cancer Care in Botswana: Current Status and Future Prospects
Swart, N. C., Lebelonyane, R., Gutterman, E. M., Legwaila, M., Friebel, T. M., Antony, R., Mayer, T. M., Sharma, K., Lall, N., Kania, B. E., et al. (2024) · JCO Global Oncology · doi:10.1200/go.24.00196 · Cited by 2
Henry, N. L., Unger, J. M., Vaidya, R., Darke, A. K., Skaar, T. C., Fisch, M. J., & Hershman, D. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107712 · Cited by 2
Early breast cancer in young BRCA carriers: from diagnosis to treatment and survivorship
Borea, R., Arecco, L., Nardin, S., Chiappe, E., Lanzavecchia, C., Gil, M. F., Meacci, A., Hoang, G. P., Weis, L. N., Leite, L. D. M., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251368733 · Cited by 2
Hackshaw‐McGeagh, L., Stewart, S.-J., Norris, R. P., Wells, M., Thompson, S. E., Mawson, P., Brett, J., Turner, M., Wolstenholme, J. L., Dakin, H., et al. (2025) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2025.103026 · Cited by 2
Radwan, E., Memoli, V., Seguin, L., Mancini, J., & Bouhnik, A. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07840-1 · Cited by 2
Janelsins, M. C., & Magnuson, A. M. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.5088 · Cited by 2
McCall, M. K., Sereika, S. M., Snader, S., Lavanchy, A., Rosenzweig, M. Q., Conley, Y. P., Beumer, J. H., & Bender, C. M. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07326-6 · Cited by 2
Joyce, E. V., Tao, X., Stearns, V., Hayes, D. F., Storniolo, A. M., Kidwell, K., & Henry, N. L. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07218-1 · Cited by 2
Millard, T. A., Turkheimer, L. M., Petroni, G. R., Brighton, D., Meneveau, M. O., Obidike, P. C., McGuire, K. P., & Showalter, S. L. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17861-1 · Cited by 2
pS6K1 as an efficacy marker of GnRH agonist with premenopausal breast cancer
Park, C. S., Choi, J., Seong, M.-K., Hong, S., Kim, J., Park, I., Seol, H., Noh, W. C., & Kim, H. (2019) · Endocrine Connections · doi:10.1530/ec-19-0101 · Cited by 2
Lee, A. Y., Lyons, A. T., Makris, V., Kamaraju, S., Stolley, M. R., Neuner, J. M., & Flynn, K. E. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08463-w · Cited by 2
Li, C., Malapati, S. J., James, L. P., & Hutchins, L. F. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.07.009 · Cited by 2
Kadakia, K. C., & Henry, N. L. (2014) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2014.07.015 · Cited by 2
Challenges of Endocrine Therapy in Breast Cancer
Mansouri, S., Teymourzadeh, A., Farahmand, L., & Majidzadeh‐A, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-64550-6_17 · Cited by 2
Lin, D., Goldberg, J. D., Hochman, T., Levinson, B. A., Khan, M. R., Newman, E., Leichman, L. P., & Gold, H. T. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0996-6 · Cited by 2
Broman, K. K., Joya, L. E., Sun, W., Zhou, J., Fridley, B. L., Javedan, K., Diaz, R., & Laronga, C. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05490-6 · Cited by 2
Taylor, C., & Meisel, J. L. (2021) · Cancer · doi:10.1002/cncr.33595 · Cited by 2
Kaviani, A., Bourque, J., Farazmand, B., & Salmon, R. J. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01630 · Cited by 2
Rattsev, I., Stearns, V., Blackford, A. L., Hertz, D. L., Smith, K. L., Rae, J. M., & Taylor, C. O. (2024) · JAMIA Open · doi:10.1093/jamiaopen/ooae006 · Cited by 2
Tawfik, B., Jacobson, K. A., Brown-Glaberman, U. A., Kosich, M., Horn, M. L. V., Nemunaitis, J. M., Dayao, Z. R., Pankratz, V. S., Sussman, A. L., & Guest, D. D. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01261-4 · Cited by 1
How to Optimize Deimplementation of Sentinel Lymph Node Biopsy?
Dragvoll, I., Bofin, A. M., Søiland, H., & Engstrøm, M. J. (2024) · The Breast Journal · doi:10.1155/2024/7623194 · Cited by 1
Neuner, J. M., Stolley, M. R., Kamaraju, S., Tiegs, J., Sparapani, R., Makris, V., & Flynn, K. E. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07513-5 · Cited by 1
Seo, Y., Hudmon, K. S., Jones, K. L., Yih, Y., Miller, K. D., & Abebe, E. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251323205 · Cited by 1
Battelli, N., Mocerino, C., Montedoro, M., Pistelli, M., Portarena, I., Rosanova, M., Sidoni, T., & Vici, P. (2025) · Current Oncology · doi:10.3390/curroncol32040192 · Cited by 1
Socioeconomic disparities and osteoarthritis impact hormone therapy adherence in breast cancer
Jang, B., Chang, J., & Shin, K. H. (2025) · The Breast · doi:10.1016/j.breast.2025.104476 · Cited by 1
Cocozza, T., Smith, R. M., López, A. M., Rudoler, S. B., Slamon, R., Zhan, T., Vega, J. L., Dhamankar, M., Padmanabhan, A., Miller, S. M., et al. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22050734 · Cited by 1
Using Large Language Model for Efficient Extraction of Treatment Discontinuation Information
Song, Q., Yang, X. J., Obi, N., Ni, C., Warner, J. L., Chen, Q., Song, L., Rosenbloom, S. T., Malin, B., & Yin, Z. (2025) · Lecture notes in computer science · doi:10.1007/978-3-031-95841-0_70 · Cited by 1
Johnson, A. T., Vuylsteke, P., Ntloedibe, T., Reyes, J. E. M., John, O., Wester, J. R., Chiao, E. Y., & Dryden‐Peterson, S. (2025) · Breast Care · doi:10.1159/000547028 · Cited by 1
Adherencia a la terapia hormonal en mujeres con cáncer de mama
Alzate, K. P., Lema, C., Lema, M., & García, P. (2025) · Colombia medica · doi:10.25100/cm.v56i2.6613 · Cited by 1
Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines
Verreck, E. E. F., Postma, E. L., Oostergo, T., Meijer, J., Eijkelboom, A. H., Siesling, S., Rizopoulos, D., van Dalen, T., & Volders, J. H. (2025) · The Breast · doi:10.1016/j.breast.2025.104664 · Cited by 1
Bu, D., Sahu, A., & Torres, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1704927 · Cited by 1
Kean, E. A., & Adeleke, O. A. (2026) · Targets · doi:10.3390/targets4030025 · Cited by 1
Les défis actuels en cancérologie dans la région de Bruxelles-capitale : une étude qualitative
Horicks, F., & Coppieters, Y. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.04.016 · Cited by 1
Green, S. M. C., Hall, L., Ellison, R., Clark, J. R., Wilkes, H., Hartley, S., Naik, J., Buckley, S., Hirst, C. M., Hartup, S. M., et al. (2025) · British Journal of Health Psychology · doi:10.1111/bjhp.12802 · Cited by 1
Hackshaw‐McGeagh, L., Walker, A., Hiller, L., Dunn, J., Wells, M., Donnelly, P. K., Wardley, A. M., Wolstenholme, J. L., Horne, R., Stewart, S.-J., et al. (2025) · Trials · doi:10.1186/s13063-025-09056-6 · Cited by 1
Gambaro, K., Rachedi, K., Basik, M., Fred Saad, C., Mes‐Masson, A., Hassan, S. N., Orimoto, A. M., Boudreau, D., Vincent, F., St‐Hilaire, È., et al. (2025) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234251395892 · Cited by 1
Qiu, A., Yang, H., Guo, J., Hou, L., Hua, Y., Su, X., Lin, Y., & Zhu, J. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s578438 · Cited by 1
Yazıcı, S., Nyback, S., Derntl, B., Ljungman, L., Hirschberg, A. L., Kallner, H. K., Poromaa, I. S., Wikman, A., & Kallak, T. K. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109010 · Cited by 1
Learning Hormonal Therapy Medication Adherence from an Online Breast Cancer Forum
Yin, Z., Warner, J. L., Song, L., Hsueh, P.-Y. S., Chen, C.-H., & Malin, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-14714-3_12 · Cited by 1
Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer
Chan, C. W. H., Miaskowski, C. A., McCarthy, A. L., Waye, M. M. Y., Yeo, W., So, W. K. W., Choi, K. C., Tsui, S. K., & Chan, J. Y. (2020) · Medicine · doi:10.1097/md.0000000000019083 · Cited by 1
It's not an easy fix: Adherence to adjuvant endocrine therapy after breast cancer.
Lambert, L. K., Balneaves, L. G., & Howard, A. F. (2021) · PubMed · Cited by 1
Kimmick, G. G., Pienknagura, R. A., & Weinmann, S. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-75377-1_6 · Cited by 1
Impacto das principais formas de tratamentos na qualidade de vida de pacientes com câncer de mama
Aguiar, R. D. C. S., Freitas, E. C. B. F., & Freitas, M. T. D. S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i8.30450 · Cited by 1
Quintero-Ortíz, M. A., Guzmán-Abisaab, L., Garcia-Tirado, K., Sánchez, R., Lozano, I. F. M., Lehmann-Mosquera, C., Ángel-Aristizábal, J., García, M., & Díaz, S. (2022) · Cureus · doi:10.7759/cureus.27212 · Cited by 1
Corona, R. M., Valero, C. Z. V., & Méndez, D. R. (2022) · Psicología y Salud · doi:10.25009/pys.v33i1.2786 · Cited by 1
L’adhésion à l’hormonothérapie adjuvante : un enjeu majeur dans la prise en charge du cancer du sein
Coussy, F., Robert, M., Villanueva, C., Dalenc, F., Rowinski, E., & Wassermann, J. (2024) · Bulletin du Cancer · doi:10.1016/j.bulcan.2024.05.004 · Cited by 1
Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery
Johnsson, A., & von Wachenfeldt, A. (2024) · Cancer Reports · doi:10.1002/cnr2.2160 · Cited by 1
Liberty, A. L., Edelman, A. B., & Bernhardt, S. M. (2025) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2024-202662 · Cited by 1
Millard, T. A., Turkheimer, L. M., Schlefman, J., Petroni, G. R., Brighton, D., & Showalter, S. L. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf172 · Cited by 1
Washburn, D., & Thompson, K. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.e13-e20 · Cited by 1
Yu, S. H., & Kang, J. H. (2020) · Korean Journal of Adult Nursing · doi:10.7475/kjan.2020.32.3.223 · Cited by 1
Clinical practice to address tamoxifen nonadherence
Love, R. R., Baum, M., Love, S. M., & Straus, A. M. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05912-y · Cited by 1
HORMONIOTERAPIA E O PAPEL DO FARMACÊUTICO NA ORIENTAÇÃO CLÍNICA
Pinheiro, R. T. C., & Tavares, B. D. S. C. (2023) · Editora Enterprising eBooks · doi:10.29327/5238060.1-8 · Cited by 1
Artignan, J., Capmas, P., Panjo, H., Constantinou, P., & Pelletier‐Fleury, N. (2023) · BMC Medicine · doi:10.1186/s12916-023-03156-3 · Cited by 2
Tamoxifen Pharmacokinetics Beyond the Genotyping Era
Binkhorst, L. (2015) · RePub (Erasmus University Rotterdam) · Cited by 1
Managing Breast Cancer in Young Women
Habib, J. G., & Azim, H. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-17278-1_2
Factors Influencing Treatment Adherence and Discontinuation in Women with Breast Cancer
Kasi, P. M., & Ruddy, K. J. (2015) · Breast Cancer Management · doi:10.2217/bmt.14.48
Prostate Cancer; Metabolic Risk Factors, Drug Utilisation, Adverse Drug Reactions
Grundmark, B. (2013) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Tan, X., Marshall, V., Camacho, F., Anderson, R. T., & Balkrishnan, R. (2015) · Value in Health · doi:10.1016/j.jval.2015.03.1244
Federici, L. M. (2016) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2061
Nair, N. P., Kvizhinadze, G., & Blakely, T. A. (2016) · Value in Health · doi:10.1016/j.jval.2016.05.015
Exercise in Breast Cancer Survivors
Amin, N. M., & Ring, A. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-41858-2_8
Endocrine Therapies in the Adjuvant and Advanced Disease Settings
Pagani, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_45
Exercise and drug adherence for breast cancer survivors
Yamauchi, H. (2018) · 体力科學 · doi:10.7600/jspfsm.67.165
Hormonothérapie adjuvante dans le cancer du sein
Debled, M., & Salabert, L. (2016) · Elsevier eBooks · doi:10.1016/b978-2-294-74449-5.00012-5
A Review of the Literature Evaluating Adherence and Persistence to Adjuvant Endocrine Therapy
Strickland, K. S. (2017) · Journal of Gynecology and Womens Health · doi:10.19080/jgwh.2017.07.555725
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
